Disease · MONDO_0013189

trichotillomania

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. trichotillomania. Diseases, record MONDO_0013189. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013189

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: trichotillomania; Open Targets
Open Targets ID: MONDO_0013189; Open Targets
Other names: Hair-pulling, trichotillomania, multifactorial; Open Targets
Disease Ontology: DOID:0050587; Disease Ontology
MeSH: D014256; MeSH
NCI Thesaurus: C94336; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 2 of its 10 drugs, from ClinicalTrials.gov; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DRONABINOL	CHEMBL465	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
INOSITOL	CHEMBL1222251	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SILYMARIN	CHEMBL4630684		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VALBENAZINE	CHEMBL2364639	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/1268	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor partial agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor agonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/116444	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04792645	Memantine in Body Focused Repetitive Behaviors	Phase 2	100	2023-08-01	Trichotillomania (Hair-Pulling Disorder), Dermatillomania	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT00775229	Naltrexone in the Treatment of Trichotillomania	Phase 2	51	2014-03-17	Trichotillomania	NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00354770	N-Acetyl Cysteine in Trichotillomania	Phase 2	50	2014-01-15	Trichotillomania	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT03530800	Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors	Phase 2/3	50	2022-06-02	Trichotillomania, Skin-Picking	DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT00993265	N-Acetylcysteine for Pediatric Trichotillomania	Phase 2	39	2014-07-25	Trichotillomania, Hair Pulling	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT01875445	Inositol in Trichotillomania	Phase 2	38	2017-05-19	Trichotillomania, Hair Pulling	INOSITOL	Its record names the disease	ClinicalTrials.gov
NCT02473913	Milk Thistle in Trichotillomania in Children and Adults	Phase 2	22	2020-11-04	Trichotillomania, Hair Pulling Disorder	SILYMARIN	Its record names the disease	ClinicalTrials.gov
NCT01093976	Marinol in Trichotillomania or Obsessive Compulsive Disorder	Phase 2	14	2013-09-27	Trichotillomania, Obsessive Compulsive Disorder	DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT00947154	Trial of Aripiprazole in Trichotillomania	Not applicable	12	2015-06-16	Trichotillomania	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT05545891	Aripiprazole in Body Focused Repetitive Behaviors	Phase 2	100		Trichotillomania (Hair-Pulling Disorder), Dermatillomania	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Memantine vs Placebo: deaths from any cause	0 of 55	0 of 45	100	NCT04792645	Trial comparisons
Memantine vs Placebo: serious adverse events	0 of 55	0 of 45	100	NCT04792645	Trial comparisons
Memantine vs Placebo: Clinical Global Impressions-Improvement Scale (CGI-I)	26 of 43	3 of 36	79	NCT04792645	Trial comparisons
Naltrexone vs Placebo: serious adverse events	0 of 25	0 of 26	51	NCT00775229	Trial comparisons
N-Acetyl Cysteine vs Placebo: serious adverse events	0 of 25	0 of 25	50	NCT00354770	Trial comparisons
Dronabinol vs Placebo: deaths from any cause	0 of 25	0 of 25	50	NCT03530800	Trial comparisons
Dronabinol vs Placebo: serious adverse events	0 of 25	0 of 25	50	NCT03530800	Trial comparisons
N-acetylcysteine (NAC) vs Placebo: serious adverse events	0 of 20	0 of 19	39	NCT00993265	Trial comparisons
Milk Thistle vs Placebo: deaths from any cause	0 of 18	0 of 21	39	NCT02473913	Trial comparisons
Milk Thistle vs Placebo: serious adverse events	0 of 18	0 of 21	39	NCT02473913	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21694623	RESULT	1	PubMed
34825898	DERIVED	1	PubMed
34582562	DERIVED	5	PubMed
26139231	DERIVED	1	PubMed
23452681	DERIVED	1	PubMed
23452680	DERIVED	1	PubMed
23251869	DERIVED	2	PubMed
21590520	DERIVED	1	PubMed
19581567	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0013189

GET https://conductscience.org/api/diseases/v1/MONDO_0013189/drugs

API reference For AI assistants